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Background: The long non-coding RNAs (lncRNAs) study has gradually become one of the hot topics in the field
of RNA biology. One lncRNA which has attracted attention is LOC285194, a lncRNA demonstrated the potential
tumor-suppressor role in osteosarcoma. The aim of this study was to examine the expression of LOC285194 in
colorectal cancer (CRC) patients and to investigate the relationship between this lncRNA levels and existing
clinicopathologic parameters and patient survival.
Methods: The expression of LOC285194 was detected by quantitative real-time polymerase chain reaction in pairs
of tumorous and adjacent normal tissues of 81 colorectal cancer patients with a follow-up of 5 years, as well as in
three colorectal cancer cell lines and normal intestinal mucous cell line. Then, we analyzed the potential
relationship between this lncRNA levels in tumor tissues and existing clinicopathological features of CRC, and
clinical outcome.
Results: The relative expression levels of LOC285194 was significantly lower in tumor tissues (p < 0.001) and
colorectal cancer cell lines compared with adjacent normal tissues and normal intestinal mucous cell line.
In addition, low expression of LOC285194 was correlated with larger tumor size (p = 0.015), higher tumor stage
(p = 0.034), and more distant metastasis (p = 0.046). Kaplan-Meier analysis indicated that patients with low
LOC285194 expression had a poor disease free survival (p = 0.010). Moreover, multivariate analysis showed that
decreased expression of LOC285194 was an independent predictor of disease-specific survival.
Conclusion: Our data indicate that LOC285194 might be a novel prognostic indicator in colorectal cancer and may
be a potential target for diagnosis and gene therapy.
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Colorectal cancer (CRC) is the third most prevalent can-
cer and the second most common cause of cancer-
related death in the world, with an annual death rate
exceeding 608,700 according to the National Cancer In-
stitute [1]. Most cases of CRC arise sporadically and
usually progress from benign polyp to malignant adeno-
carcinoma and distant metastasis. For accurate diagno-
sis and adequate treatment of CRC, identification and* Correspondence: dx2008cn@yahoo.com.cn
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reproduction in any medium, provided the orunderstanding of the molecules responsible for cancer
progression are critical.
Except for about 2% protein-coding genes, the vast
majority of the human genomes are non-coding RNAs
(ncRNAs) [2], implicating that ncRNAs could play
significant regulatory roles in complex organisms. The
function and clinical significance of short regulatory
ncRNAs, such as microRNAs (miRNAs) and small-
interfering RNAs (siRNAs) were elucidated first and then,
long ncRNAs (lncRNAs) were reported more recently.
LncRNAs have been shown to be spliced, polyadenylated,
and developmentally regulated in eukaryotes, including
antisense, intergenic transcripts and epigenetic regulators.
Many studies strongly suggested that deregulated expres-
sion of lncRNAs is closely correlated with the diversity ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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showed that some lncRNAs exhibit distinct gene ex-
pression patterns in solid tumors and leukemias [4-8].
Functional lncRNAs can be used for cancer diagnosis
and prognosis, and serve as potential therapeutic tar-
gets, we consider them as a new cancer diagnostic and
therapeutic gold mine in the future [9].
The LOC285194 gene is 2105 nt in length, located in
chr3q13.31, consisting of four exons. LOC285194 is a
lncRNA that showed loss of expression in primary
osteosarcoma samples and cell lines. In addition, deple-
tion of LOC285194 attributed to proliferation of normal
osteoblasts through regulation of apoptotic and cell cycle
transcripts and VEGF/VEGFR1. Moreover, genetic dele-
tions of LOC285194 were associated with poor survival
of osteosarcoma patients [10]. These data demonstrated
the potential tumor-suppressor role of LOC285194 in
osteosarcoma; however, the relationship between expres-
sion of LOC285194 and CRC development and/or pro-
gression remains unclear.
In the current study, we clarified the clinical signifi-
cance of LOC285194 expression in CRC. The primary
aim of this study was to investigate whether LOC285194
is detectable and altered in colorectal cancer tissues or
cell lines compared with adjacent normal tissues or nor-
mal cell line. Then, a potential relationship between this
lncRNA levels in tumor tissues and existing clinicopath-
ological features of CRC, such as tumor size, location,
histologic stage, depth of invasion, the status of lymph-
atic metastasis, venous invasion, nervous invasion, dis-
tant metastasis and disease-specific survival (DSS), was
investigated.
Methods
Cell lines, tissue samples and clinical data collection
A total of 81 patients analyzed in this study underwent
resection of the primary CRC at Fudan University
Shanghai Cancer Center. The diagnosis of CRC was
histopathologically confirmed. No patient received pre-
operative treatment. Resected tissue samples were im-
mediately frozen in liquid nitrogen, and stored at −80°C
until RNA extraction. The data collected on all subjects
include age, gender, DSS and CRC features such as
tumor size, location, histologic stage, depth of invasion,
the status of lymphatic metastasis, venous invasion, ner-
vous invasion, and distant metastasis. Clinical stage of
CRC was evaluated on the basis of the TNM classifi-
cation system [11]. Patient follow-up was performed
every 2–3 months during the first year after surgery and
3–6 months thereafter until November 30, 2012. All pa-
tients had completed follow-up. The DSS was defined as
the length of time between the surgery and death specif-
ically from the cancer. During follow-up, 20 patients
died of CRC. This study was approved by The ClinicalResearch Ethics Committee of Fudan University Shanghai
Cancer Center, and informed consent was obtained from
participants for the use of their tissues in this study.
The human colorectal cancer cell lines, including CaCO-
2, HCT8, LoVo and human normal intestinal mucous cell
line CCC-HIE-2 were obtained from the American Type
Culture Collection (Manassas, VA, USA). All cell lines
were maintained routinely in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum and
2 mM L-glutamine (Invitrogen, Carlsbad, CA) and were
grown at 37°C in a 10% CO2 atmosphere.RNA preparation, reverse transcription, and quantitative
real-time PCR
Total RNAs were extracted from tumorous and adjacent
normal tissues using Trizol (Invitrogen, Carlsbad, CA,
USA) following the manufacturer’s protocol. RT and qPCR
kits were used to evaluate expression of LOC285194 from
tissue samples. The 20 μL RT reactions were performed
using a PrimeScript® RT reagent Kit (Takara, Dalian,
China) and incubated for 30 min at 37°C, 5 s at 85°C, and
then maintained at 4°C. For real-time PCR, 1 μL diluted
RT products were mixed with 10 μL of 2 × SYBR® Premix
Ex Taq™ (Takara, Dalian, China), 0.6 μL forward and re-
verse primers (10 μM), and 8.4 μL Nuclease-free water in
a final volume of 20 μL according to manufacturer
instructions. The primers used in this study were 5’-
TGTGCCTGTTTGACCTCTGA-3’ (forward) and 5’-
AGGAAGGATAAAAGACCGACCA-3’ (reverse). All
reactions were run on the Eppendorf Mastercycler EP
Gradient S (Eppendorf, Germany) using the following con-
ditions: 95°C for 30 s, followed by 40 cycles at 95°C for
5 s, and 60°C for 30 s. Real-time PCR was done in tripli-
cate, including no-template controls. Amplification of the
appropriate product was confirmed by melting curve
analysis following amplification. Relative expression of
LOC285194 was calculated using the comparative cycle
threshold (CT) (2−ΔΔCT) method with glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as the endogenous
control to normalize the data.Statistical analysis
All statistical analyses were performed using SPSS 20.0
software (IBM, SPSS, Chicago, IL, USA). The signifi-
cance of differences between groups was estimated by
Student’s t-test, χ2 test or Wilcoxon test, as appropriate.
DSS rates were calculated by the Kaplan-Meier method
with the log-rank test applied for comparison. Variables
with a value of p < 0.05 in univariate analysis were used
in subsequent multivariate analysis on the basis of Cox
proportional hazards model. Two-sided p-values were
calculated, and a probability level of 0.05 was chosen for
statistical significance.
Figure 2 Expression of LOC285194 in three colon cancer cell
lines and normal intestinal mucous cell line. LOC285194
expression levels were determined by quantitative real-time
polymerase chain reaction in 3 colon cancer cell lines (CaCO-2,
HCT8, and LoVo cells) and normal intestinal mucous cell line
(CCC-HIE-2). Data are means ± SEM (n = 3). *Significantly different
from control (p < 0.05).
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Expression of LOC285194 in tissues and cell lines
The first goal of the present study was to investigate
whether LOC285194 is detectable and altered in colo-
rectal cancer tissues compared with adjacent normal tis-
sues. Using RNA isolated from tissues, we performed
RT-qPCR to detect the expression levels of LOC285194.
Using GAPDH as normalization control, LOC285194
expression was significantly lower in tumor tissues com-
pared with adjacent normal tissues (p < 0.001; Figure 1).
RT-qPCR assays were further developed to quantify
LOC285194 in colorectal cancer cell lines, including
CaCO-2, HCT8, LoVo cells, and normal intestinal mucous
cell line CCC-HIE-2. A significant low expression of
LOC285194 was found in LoVo (p = 0.02) compared to
CCC-HIE-2, but there was no significant difference for
CaCO-2 (p = 0.127) and HCT8 (p = 0.075, Figure 2).
LOC285194 expression and clinicopathologic factors in
CRC
To assess the correlation of LOC285194 expression with
clinicopathologic data, the expression levels of LOC285194
in tumor tissues were categorized as low or high in relation
to the mean value. Clinicopathologic factors were analyzed
in the high and low LOC285194 expression groups
(Table 1). The low LOC285194 group (n = 48) showed
larger tumor size, higher tumor stage and more distant
metasatsis than the higher LOC285194 expression
group (n = 33; p < 0.05). However, there was no signifi-
cant correlation between LOC285194 expression andFigure 1 LOC285194 expression levels assessed by quantitative
real-time PCR in cancerous tissue and adjacent normal mucosa.
The LOC285194 expression levels were normalized to GAPDH.
LOC285194 expression was significantly lower in cancerous tissues
compared with noncancerous tissues. Data are means ± SEM (p < 0.001).other clinicopathologic features, such as age, gender,
tumor location, histologic grade, lymphatic metastasis,
venous invasion or nervous invasion (p > 0.05; Table 1).Correlation between LOC285194 expression and
prognosis of CRC patients
Disease-specific survival (DSS) curves were plotted
according to LOC285194 expression level by the Kaplan-
Meier method. During follow-up, 20 patients died of
CRC. As shown in Figure 3, patients with low LOC285194
expression had a significantly poorer prognosis than
those with high LOC285194 expression (p = 0.010).
Univariate analysis of DSS revealed that the relative
level of LOC285194 expression (p = 0.019), histologic
grade (p = 0.002), tumor depth (p = 0.017), lymphatic
metastasis (p = 0.001), venous invasion (p = 0.019), ner-
vous invasion (p = 0.048), distant metastasis (p < 0.001),
and tumor stage (p = 0.001) were prognostic indicators
(Table 2). The other clinicopathological features, such as
age, gender, tumor location, and tumor size, were not sta-
tistically significant prognosis factors (p > 0.05; Table 2).
Variables with a value of p < 0.05 were selected for
multivariate analysis. Multivariate analysis showed that
LOC285194 expression was an independent prognostic in-
dicator for DSS in patients with CRC (p = 0.034) in
addition to presence of lymphatic metastasis (p = 0.017)
and distant metastasis (p = 0.006) (Table 3).
Table 1 Relationship between LOC285194 expression and clinicopathologic parameters of colorectal cancer patients
Characteristics Number
of case
LOC285194 expression p value
High (n = 33) % Low (n = 48) %
Age (years) 81 55.2 ± 11.5 57.4 ± 11.3 0.225
Gender 0.339
Male 39 18 54.5 21 43.8
Female 42 15 45.4 27 56.2
Tumor size 0.015**
<4 cm 36 20 60.6 16 33.3
≥4 cm 45 13 39.4 32 60.4
Location 0.064
Colon 44 22 66.7 22 45.8
Rectum 37 11 33.3 26 54.2
Histologic grade 0.752
Well/moderately 58 23 69.7 35 72.9
Poorly/others 23 10 30.3 13 27.1
Depth of invasion 0.529
T1,T2 23 9 27.3 14 29.2
T3,T4 58 24 72.7 34 70.8
Lymphatic metastasis 0.052
Absent 46 23 69.7 23 47.9
Present 35 10 30.3 25 52.1
Venous invasion 0.209
Absent 55 25 75.8 30 62.5
Present 26 8 24.2 18 37.5
Nervous invasion 0.229
Absent 69 30 90.9 39 81.2
Present 12 3 9.1 9 18.8
Distant metastasis 0.046**
Absent 65 30 90.9 35 72.9
Present 16 3 9.1 13 27.1
Tumor stage* 0.034**
I and II 45 23 69.7 22 45.8
III and IV 36 10 30.3 26 54.2
* Tumor stage was obtained according to the TNM criteria. ** p < 0.05.
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LncRNAs have been recently implicated as having on-
cogenic and tumor suppressor roles. One example of
such an oncogenic lncRNA is Hox transcript antisense
intergenic RNA (HOTAIR). HOTAIR expression was low
in normal breast epithelia but high in primary breast can-
cer as well as metastatic lesions, HOTAIR expression level
was a powerful predictor of patient outcomes [12]. In an-
other study, HOTAIR expression levels were higher in
cancerous tissues than in corresponding noncancerous tis-
sues of stage IV CRC patients and those patients with high
HOTAIR expression had a relatively poorer prognosis,
linking a lncRNA with cancer invasiveness and patientprognosis [13]. Another classic oncogenic lncRNA is
Metastasis-Associated Lung Adenocarcinoma Transcript 1
(MALAT-1), which was widely expressed in normal hu-
man tissues [14,15], but was upregulated in six other types
of cancer [16-20]. In addition, increased expression of
MALAT-1 has been recently shown to be an independent
prognostic factor for HCC following liver transplantation
[21] and non-small cell lung cancer [22].
Tumor-suppressor lncRNAs could phenotypically affect
cells by promoting tumor-suppressor pathways, and when
their function is compromised, cells are prone to develop
cancer. In support of this notion, a few studies have eluci-
dated several examples of ‘tumor-suppressor lncRNAs’.
Figure 3 Kaplan-Meier survival curves according to LOC285194
level. Patients with low LOC285194 expression (n = 48) had a
significantly poorer prognosis than those with high LOC285194
expression (n = 33, p = 0.010). P-value was calculated by
Log-Rank test.
Table 2 Univariate analysis of clinicopathological factors
for disease-specific survival
Variable N Hazard ratio 95% CI p value
Age (years)
<56 35 1
≥56 46 0.754 0.314-1.812 0.528
Gender
Male 39 1
Female 42 0.734 0.304-1.772 0.492
Tumor size
<4 cm 36 1
≥4 cm 45 0.774 0.322-1.859 0.556
Location
Colon 44 1
Rectum 37 1.030 0.421-2.521 0.948
Histologic grade
Well/moderately 58 1
Poorly/others 23 4.020 1.662-9.726 0.002*
Depth of tumor
T1,T2 23 1
T3,T4 58 4.870 0.737-4.531 0.017*
Lymphatic metastasis
Absent 46 1
Present 35 3.664 1.009-6.587 0.001*
Venous invasion
Absent 55 1
Present 26 2.362 0.982-5.680 0.019*
Nervous invasion
Absent 69 1
Present 12 3.605 1.434-9.064 0.048*
Distant metastasis
Absent 65 1
Present 16 0.076 0.019-0.294 <0.001*
Tumor stage
I and II 45 1
III and IV 36 3.453 0.468-4.476 0.001*
LOC285194
Low 48 1
High 33 3.201 1.318-7.774 0.019*
N. number of patients, CI. confidence interval. * <0.05.
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observed to be downregulated in breast cancer, perhaps to
sensitize cells to apoptosis by regulating the activity of
glucocorticoids in response to nutrient starvation [23,24].
In addition, genetic aberrations at the GAS5 locus have
been found in many types of tumors, including melanomas
and breast and prostate cancers [25,26], though their func-
tional significance has not yet been established. Another
tumor-suppressor lncRNA is lincRNA-p21, which acts as a
transcriptional repressor in the canonical p53 pathway and
plays a role in triggering apoptosis [27]. These data demon-
strated the potential tumor-suppressor role of lncRNAs;
however, the relationship between tumor-suppressor
lncRNA and cancer patient prognosis remains unclear.
Recently, Pasic and colleagues have characterized a re-
gion of chr3q13.31, designated osteo3q13.31, which har-
bors frequent focal copy number alterations (CNAs) and
loss of heterozygosity (LOH) in primary osteosarcoma
samples and cell lines [10]. They found that most
osteo3q13.31 CNAs involve two ncRNAs, LOC285194
and BC040587 and, sometimes, the limbic system-
associated membrane protein (LSAMP) tumor suppres-
sor (TS). In addition, they showed the most effect
of osteo3q13.31 CNAs on LOC285194 expression by
RT-qPCR among 43 primary osteosarcoma tumor biop-
sies and 5 osteosarcoma cell lines. Interestingly, focal
osteo3q13.31 biallelic deletions were common in cell
lines from various cancers, including gastrointestinal
tract. Given the potential roles of lncRNAs in tumor-suppressive pathways, we speculated that LOC285194
was also misregulated in CRC development and/or pro-
gression. This functional lncRNA may also link to prog-
nosis of CRC patients. To support of these hypotheses,
we firstly investigated whether LOC285194 is detectable
and altered in 81 pairs of colorectal cancer tissues and
adjacent normal tissues by RT-qPCR. Then, a potential
Table 3 Multivariate analysis of clinicopathological
factors for disease-specific survival
Variable HR 95% CI p value
Histologic grade (poor, others/well, mod) 1.649 0.566-4.801 0.348
Depth of tumor (T3,T4/T1,T2) 2.843 0.069-1.652 0.279
Lymphatic metastasis (present/absent) 1.138 0.001-9.942 0.017*
Venous invasion (present/absent) 0.726 0.215-2.445 0.605
Nervous invasion (present/absent) 0.674 0.184-2.469 0.551
Distant metastasis(present/absent) 2.076 1.642-8.802 0.006*
Tumor stage (III + IV/I + II) 1.520 0.006-5.374 0.156
LOC285194 (low/high) 0.337 0.083-4.367 0.034*
HR. Hazard ratio, CI. Confidence interval, well. well-differentiated, mod.
moderately differentiated, poor. poorly differentiated, * < 0.05.
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sues and existing clinicopathological features of CRC,
such as tumor size, location, histologic stage, depth of
invasion, the status of lymphatic metastasis, venous in-
vasion, nervous invasion, distant metastasis and disease
free survival, was investigated.
Using GAPDH as normalization control, we con-
firmed that LOC285194 expression was significantly
lower in 81 tumor tissues compared with adjacent
normal tissues (p < 0.001). Additionally, LOC285194 ex-
pression is markedly decreased in LoVo colorectal can-
cer cell lines compared with normal intestinal mucous
cell line using RT-qPCR assays (p = 0.02). The low
LOC285194 group showed larger tumor size, higher
tumor stage and more distant metasatsis than the higher
LOC285194 expression group. Moreover, we found that
low LOC285194 expression patients had a significantly
poorer prognosis than those with high LOC285194 ex-
pression, consistent with reports of tumor-suppressive role
of LOC285194 in osteosarcoma [10].
The precise molecular mechanisms behind the altered
expression of LOC285194 in CRC are unclear. In osteosar-
coma, changes in expression of LOC285194 could be
explained by CNAs at osteo3q13.31 [10]. Colorectal car-
cinogenesis is a complex, multistep and multifactorial
event, whether low expression of LOC285194 was associ-
ated with CNAs at 3q13.31 in CRC remains to be eluci-
dated. In addition, the effects of altered expression of
LOC285194 in the development and/or progression of
CRC are fascinating. Pasic and colleagues have demon-
strated that depletion of LOC285194 can not only pro-
mote cell growth in MTT assays, but also increase the G1
population in cell cycle analysis. However, depletion of
LOC285194 mRNA had no effect on osteoblast migration.
This implicates LOC285194 as functional growth suppres-
sor in osteoblasts in vitro. The way that lncRNA regulates
the expression of its target genes is very complex.
LOC285194 can act as growth suppressors through regu-
lation of apoptotic and cell cycle transcripts and VEGF/VEGFR1 in osteoblasts [10]. Nevertheless, since it’s highly
possible that target genes of lncRNA differ between spe-
cific tissues and cell types, specific target genes controlled
by LOC285194 for CRC remained unknown, whether or
not it also regulates VEGF/VEGFR1 and BCL2 will require
detailed investigation. In future work, high-throughput
techniques should be applied to obtain a global view on
the changes of mRNA molecules and to elucidate the
mechanisms of regulation of LOC285194.
Conclusion
Our results showed that LOC285194 expression was sig-
nificantly decreased in colorectal cancer tissues and cell
lines. A lower expression of LOC285194 was detected in
tumor of larger size, higher tumor stage and with distant
metastasis. In addition, the downregulation expression of
LOC285194 was associated with poor prognosis. These
findings suggested that LOC285194 might be a novel
prognostic indicator in CRC and may be a potential target
for diagnosis and gene therapy.
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